Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

TOKYO & BASKING RIDGE, N.J., March 31, 2025--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination ...

NEW YORK, March 31, 2025--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company ...

We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung cancer cell line. Single guide RNAs (sgRNAs) designed and ...